Latest News in Neuroendocrine Tumours
Clinical benefit demonstrated with everolimus and pasireotide LAR alone or in combination in the first randomised, prospective study entirely dedicated to advanced lung and thymic carcinoids. In patients with advanced [...]
CNETS Canada is looking to gain insight into the Canadian neuroendocrine (NET) cancer patient experience with Gallium 68 scans to date. This information will assist us in developing next steps [...]
One way that CNETS Canada honours those individuals who have made an outstanding commitment and contribution to the NET cancer patient community is through our annual Maureen Coleman award. Maureen [...]
“Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs” – a collaborative effort between the International Neuroendocrine Cancer Alliance (INCA) and [...]
Over the last several years CNETS Canada has worked hard to continuously improve our website and the information contained in it to ensure that it is highly functional and as [...]
CNETS Canada's President, Jackie Herman is quoted in Maclean’s Magazine Digestive Health Supplement
This past March CNETS Canada held its first Scientific and Medical Advisory Board (SMAB) meeting in Toronto. The SMAB is composed of prominent Canadian physicians and scientists passionate about the [...]
Neuroendocrine Tumour (NET) Incidence Significantly Increases in Canada An original article published in Cancer, February 15, 2015, by the American Cancer Society showed that the incidence of Neuroendocrine Tumours has [...]